Price transparency led patients to choose lower-cost hospitals

When given access to transparency tools estimating prices for imaging services and sleep studies, commercially-insured patients were more likely to choose lower-cost hospitals.

The study, published in JAMA Internal Medicine, linked enrollment and medical claims data from 2010 to 2012 to search results from patients aged 19 to 64 years old for the following procedures: carpal tunnel release, cataract removal, colonoscopy, echocardiogram, mammogram, several MR and CT imaging services, sleep studies or upper endoscopy.

To isolate the effect off seeing the price estimates, researchers compared whether patients who viewed estimates for their specific procedure were more likely to choose lower-priced facilities than those searching for other procedure or who had the procedure performed in the year before the pricing tool was widely available.

According to their results, the ability to look up prices had an impact. For both the imaging services and sleep studies, patients who viewed price estimates chose facilities with lower estimates than other patients. They also saved money, with searching for prices being associated with lower adjusted spending of $131.40 for imaging and $103.50 for sleep studies.

“This study focused on one carrier, and data include the first two years that the tool was available; future research is needed to determine whether these patterns hold if and when these tools are used more broadly,” wrote Anna D. Sinaiko, PhD, MPP, of Harvard University’s T.H. Chan School of Public Health and her coauthors. “We also cannot observe whether patients used the tool not to comparison shop but to become educated on costs in advance of receiving medical care.”

Sinaiko and her coauthors concluded by saying barriers to using the tool may remain due to few patients taking advantage of it and “modest effects for other services.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.